ClinicalTrials.gg
RecruitingNCT07555665REPLACEUpdated Apr 29, 2026

REal Word aPpLicAtion of Molecular Based Endometrial Cancer Classification

An observational study in Endometrial Cancer, sponsored by Fondazione Policlinico Universitario Agostino Gemelli IRCCS. Recruiting at 1 site in Italy. Per ClinicalTrials.gov, last updated 2026-04-29.

Sponsored by Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Jun 2026, 5 months ago, but the record still lists the study as recruiting.
  • Started Nov 2025; still recruiting 1 year later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Cross-sectional
Enrollment
264
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 17 studies in Endometrial Neoplasms by Fondazione Policlinico Universitario Agostino Gemelli IRCCS — 15 open to participants now, 16 under way, none of them phase 3. Endometrial Neoplasms · Fondazione Policlinico Universitario Agostino Gemelli IRCCS.

Planned enrollment
5th of 12
264 · median 160
Started
2025
with 5 others
Observational
12 of 17
11 open now
Primary completion
2026-06
later than 8 of 15 live
Registered
15th of 17
by date

Among the 17 studies in Endometrial Neoplasms by Fondazione Policlinico Universitario Agostino Gemelli IRCCS, this one is the 5th largest by planned enrollment of the 12 observational ones that give a count, is one of 6 that started in 2025, is one of 12 observational ones, reaches primary completion later than 8 of the 15 other live ones, and was the 15th registered.

Endometrial Neoplasms

1,429 studies on the registry are indexed under Endometrial Neoplasms; 470 are open to participants now.

Browse Endometrial Neoplasms studies →

Open to participants now

15 of the 17 studies in Endometrial Neoplasms by Fondazione Policlinico Universitario Agostino Gemelli IRCCS are open now, in 1 country. Recruiting first, the newest first:

9 more — sign in →

By country, each count listing its studies:

All 15 open studies →

Where they have run

Who these studies take

Of the 356 Endometrial Neoplasms studies recruiting now, 266 (75%) set no upper age limit and 54 (15%) stop at 75 or younger; 26 take children under 18; 23 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies in Endometrial Neoplasms by Fondazione Policlinico Universitario Agostino Gemelli IRCCS, or all of them as a file.
02

Study summary

Despite the high incidence, endometrial cancer represents a low mortality neoplasma due to the high prevalence of early-stage diagnosis (90%). Concerning the uterine-confined disease (FIGO 2009 and 2023 stage I-II), molecular-based classification has showed an unprecedent impact on the treatment algorithm leading to a full integration into the latest staging classification. The first evidence of the prognostic value of molecular subgroups came from the TCGA data in which patients were subdivided into: patients with POLE gene alterations, MMR deficient (MMRd), patients with TP53 gene mutations, absence of one of these alterations (NSMP). The use of molecular classification reveals distinct prognostic groups ranging from an excellent prognosis (POLE mutated) to those with a worst prognosis (p53 mutated). Therefore, according to the ESGO guidelines, in patients with stage I-II POLE mutated endometrial cancer, the recurrence rate is so low as to justify omitting adjuvant treatment in favor of observation alone. Several groups have applied a diagnostic algorithm using five immunohistochemical markers (p53, MLH1, MSH2, MSH6 and PMS2) and a molecular test (analysis of mutations in the exonuclease domain of POLE) to identify prognostic groups similar to the molecular classification of TCGA. The feasibility of this approach has been confirmed by many publications that have all consistently reported prognostic relevance especially in high-grade and high-risk tumours in several independent cohorts and prospective clinical trials.

In conclusion, despite the validation of immunohistochemical evaluation in place of molecular evaluation, the need to perform a more complex evaluation to define POLE status makes its implementation not yet ubiquitous.

The integration of molecular analysis of the POLE mutations remains challenging across the centers involved in the management of endometrial cancer.

REPLACE is a national, cross-sectional survey that will census all Italian gynaecology centres (≈ 264) involved in the endometrial cancer treatment into: (i) quantify POLE testing adoption, (ii) describe diagnostic methodologies, (iii) map treatment de-escalation strategies triggered by POLE status, and (iv) explore management pathways where POLE is unavailable. Findings will highlight implementation gaps and inform future network initiatives.

Read the detailed description

Endometrial carcinoma is the most common gynecological cancer in Europe, with an incidence of 420.368 new cases in 2022 and a low mortality (97.300) due to a high prevalence (90%) of early stage at diagnosis. In 2013, the TCGA succeeded in defining 4 molecular subgroups (POLE mutated patients, high microsatellite instability [MSI-H], TP53 mutated patients or none of these alterations) significantly associated with prognosis. In particular, patients with POLEmut tumors demonstrate an excellent prognosis, while those with mutations in TP53 exhibit a poorer prognosis. Endometrial carcinomas with MSI-H fall within an intermediate prognostic range.

Based on this data, different groups developed and validated a pragmatic molecular classifier leveraging surrogate immunohistochemistry markers (p53, MLH1, MSH2, MSH6 and PMS2) identifying prognostic groups analogous to the TCGA molecular-based classification. The feasibility of this approach was confirmed by a large number of publications that have all consistently reported prognostic relevance particularly in high-grade and high-risk tumors in several independent cohorts and prospective clinical trials. Overall, a growing body of evidence had been generated, supporting the role of molecular features in understanding disease behavior, ultimately influencing staging and therapeutic decisions. Consequently, this led to the full integration of molecular data into the latest FIGO staging system and ESMO 2022 and ESGO 2025 guidelines.

Despite the absence of prospective randomized trials, the recurrence rate of patients with stage I-II POLE mutated endometrial cancer has been shown to be so low that omitting adjuvant treatment in favor of observation alone can be justified. This concept has been even strongly highlighted in the last endometrial cancer staging system, where uterine-confined POLE mutated cases are downstaged to IAmPOLEmut regardless of the presence of any other known prognostic indicator (es. Lymphovascolar space involvement, grading 3, non-endometrioid histotype).

All markers are required to be assessed to define molecular subgroups since a combination of positive tests can occur in approximatively 5% of all carcinomas (so-called 'multiple classifiers'); however, among them, POLE evaluation remains the only one requiring DNA sequencing, posing a significant challenge for many centers. In particular, only pathogenic variants of POLE identified in the gene's exonuclease domain can currently define POLE mutant cases.

In addition to the barriers faced in POLE testing, many concerns have emerged regarding tailoring staging and therapeutic algorithms in the absence of randomized clinical trials. The overall low incidence of POLE mutant cases, and the even lower association with well-recognized negative prognostic features (such as non-endometrioid histotype, lymphovascular space involvement, and MELF pattern) have further contributed to uncertainties regarding the optimal clinical management of these patients. Despite guideline endorsement, POLE sequencing is technically demanding and not uniformly available. Italy's hub-and-spoke cancer model assigns complex care to I and II levels centres; however, no national data describe POLE testing availability or its impact on therapeutical choices. Understanding current practice is a prerequisite to standardize molecularly driven care and to design interventional trials.

The primary objective is to determine the proportion of Italian gynaecology units that perform routine POLE testing in endometrial cancer surgical specimens.

This is a nation-wide, cross-sectional, web-based survey of Italian first or second level gynaecology units, coordinated by Fondazione Policlinico Universitario Agostino Gemelli IRCCS. Each partecipant centre will nominate one senior clinician (≥ 5 years EC experience) to complete the questionnaire once.

The study, in the form of a survey, aims to ask participating centres a questionnaire with multiple-choice questions. In case of adherence to survey participation, the identified referent clinician is required to answer the questionnaire within 1 month of submission; otherwise, a reminder will be sent. Subsequently, the answers will be centralized by the promoting centre, which will assess the appropriateness and quality of the data provided. The answers will also be subjected to a blind review procedure by an external reviewer. The maximum duration of the study, calculated as the time interval from survey approval to data collection, is estimated to be one year.

The survey aims to provide an insight of the application of molecular classification in endometrial cancer, particularly POLE evaluation, in experted centres for this pathology. It is expected that the questionnaire format and the blinded review will provide interesting data regarding possible problems and/or controversies of molecular driven treatment application in clinical practice.

03

Conditions studied

  • Endometrial Cancer

Keywords

  • ENDOMETRIAL CANCER
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

REPLACE is a national, cross-sectional survey that will census all Italian gynaecology centres (≈ 264) involved in the endometrial cancer treatment into: (i) quantify POLE testing adoption, (ii) describe diagnostic methodologies, (iii) map treatment de-escalation strategies triggered by POLE status, and (iv) explore management pathways where POLE is unavailable. Findings will highlight implementation gaps and inform future network initiatives.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. be Italian healthcare hospitals that are involved in the treatment of endometrial carcinoma,
  2. involved in the surgical management of EC.

Exclusion criteria

Exclusion Criteria:

a) declining to participate.

05

Study design

Observational model
Other
Time perspective
Cross-sectional
Enrollment
264 participants (estimated)
Patient registry
No

Groups and cohorts

  • Survey study asking centers to complete a multiple-choice questionnaire

    Survey study asking centers (264 centers) to complete a multiple-choice questionnaire; clinicians have 1 month to respond before a reminder is sent.

    Other: Questionnaire Submission

Interventions

  • OtherQuestionnaire Submission

    Questionnaire Submission

06

What researchers measure

Primary outcomes

  1. Prevalence of Routine POLE Testing in Surgical Specimens for Endometrial Cancer Across Italian Gynaecology Units

    To determine the proportion of Italian gynaecology units that perform routine POLE testing in endometrial cancer surgical specimens.

    Time frame: Baseline

Secondary outcomes

  1. Characterization of Laboratory Techniques and Reporting Workflows for POLE Mutation Assessment in Endometrial Cancer

    To characterize laboratory techniques (Sanger, NGS mini-panel, comprehensive genomic profiling, WES) and reporting workflows used for POLE assessment.

    Time frame: Baseline

  2. Impact of POLE Mutation Status on Adjuvant Treatment Decision-Making in Endometrial Cancer.

    To assess how POLE results influence adjuvant treatment decisions (observation vs radiotherapy vs chemotherapy).

    Time frame: Baseline

  3. Management Pathways and Adoption Readiness in Centres Without POLE Testing for Endometrial Cancer.

    Among centres not performing POLE, describe patient management pathways (external referral, treatment based on clinical staging) and interest in adopting POLE testing on-site.

    Time frame: Baseline

  4. Association Between Centre Characteristics and POLE Testing Uptake and Treatment Patterns in Endometrial Cancer

    To explore associations between centre characteristics (geography, annual EC surgical volume, research activity, clinical trial portfolio, presence of genomics lab) and POLE-testing or treatment patterns.

    Time frame: Baseline

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Nov 2025 (actual). Primary completion is estimated for Jun 2026, 6 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 11, 2026
First posted
Apr 29, 2026
StartActual
Nov 7, 2025
Primary completionEst.
Jun 1, 2026
CompletionEst.
Dec 1, 2026
Last update
Apr 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 29, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07555665
Responsible party
NERO CAMILLA (Doctor, Fondazione Policlinico Universitario Agostino Gemelli IRCCS) — Principal investigator
First posted
Apr 29, 2026
Start date
Nov 7, 2025
Primary completion
Jun 1, 2026 (estimated)
Completion
Dec 1, 2026 (estimated)
Last update
Apr 29, 2026

Study contacts

Camilla Nero CN Camilla Nero, PhD
Contact
camilla.nero@policlinicogemelli.it
0630157104
Camilla Nero
principal investigator · Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion